A Phase 3 interventional study of Paliperidone ER in Schizophrenia, sponsored by Xian-Janssen Pharmaceutical Ltd.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 26th largest by enrollment, is one of 13 that started in 2008, is one of 41 in phase 3, and was the 72nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 13 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 405 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Xian-Janssen Pharmaceutical Ltd., one of the names counted as Johnson & Johnson. Under that name alone:
Xian-Janssen Pharmaceutical Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 37th largest by enrollment of the 176 interventional ones that give a count, is one of 17 that started in 2008, is one of 74 in phase 3, and was the 159th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions [a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder] and hallucinations [imagining things], and withdrawal into the self) who were not satisfied with other prior antipsychotics (agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect; olanzapine, quetiapine and risperidone) they had been taking. The safety and tolerability of paliperidone ER tablets will also be assessed.
This is an open label (all people know the identity of the intervention), prospective (study following participants forward in time), non-randomized (the study drug is not assigned by chance, participants may choose which group they want to be in, or they may be assigned to the groups by the researchers), single-arm (getting one dose of medicine) and multi-center (when more than one hospital or medical school team work on a medical research study) study designed to determine the efficacy, tolerability and safety of flexible dosage of paliperidone ER tablets in treatment of participants with schizophrenia not satisfied with other prior antipsychotics. The duration of the study will be 12 weeks. All participants will be given paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks; initial dose for paliperidone ER will be 6 mg/day. The primary objective will be to evaluate the efficacy of treatment with paliperidone ER using Positive and Negative Symptom Scale (PANSS) total scores. Participants safety and tolerability will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Paliperidone ER
Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12
PANSS is a medical scale that assesses various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions \[a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder\] and hallucinations \[imagining things\], and withdrawal into the self). The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
Time frame: Baseline and Week 12
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Subscale Scores at Week 12
PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Positive syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. Negative syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. General Psychopathology subscale ranges from 16 to112, higher change scores indicate worsening.
Time frame: Baseline and Week 12
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Subscale Scores at Week 12
The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28. Higher change score indicates greater severity.
Time frame: Baseline and Week 12
Percentage of Participants With Response to Positive and Negative Syndrome Scale (PANSS) Total Score
PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Percentage of participants with at least 20 percent improvement of PANSS total score was measured.
Time frame: Week 12
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 12
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants". Higher change scores indicate worsening.
Time frame: Baseline and Week 12
Change From Baseline in Total Personal and Social Performance (PSP) Score at Week 12
PSP assesses the degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =\<30, functioning so poorly as to require intensive supervision.
Time frame: Baseline and Week 12
Number of Participants With Satisfaction With the Study Treatment
Participants assessed their satisfaction with paliperidone ER on a 5-point scale: 1 (very good), 2 (good), 3 (moderate), 4 (poor) and 5 (very poor).
Time frame: Baseline and Week 12
Change From Baseline in Sleep and Daytime Drowsiness Evaluation Score at Week 12
The self-administered sleep VAS scale (0-100 milimeter \[mm\]) rates quality of sleep (QoS) and daytime drowsiness (DD). Participants indicate mark on the scale to represent how well they have slept in the previous 7 days, score ranges from 0 mm (very badly) to 100 mm (very well); and how often they have felt drowsy within the previous 7 days, from 0 mm (not at all) to 100 mm (all the time).
Time frame: Baseline and Week 12
Participants were recruited from 19 study centers between 30 July 2008 and 23 September 2009.
| Milestone | Paliperidone Extended Release (ER) |
|---|---|
| Started | 403 |
| Full analysis set | 394 |
| Completed | 326 |
| Not completed | 77 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Lost to follow-up | 21 |
| Withdrew: Adverse event | 15 |
| Withdrew: Lack of efficacy | 12 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Study medication non-compliance | 3 |
| Withdrew: Other | 6 |
PANSS is a medical scale that assesses various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions \[a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder\] and hallucinations \[imagining things\], and withdrawal into the self). The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
| unit on a scale | Lack of Efficacy Group | Lack of Tolerability Group | Other Group |
|---|---|---|---|
| Baseline | 77.18 ± 17.50 | 58.46 ± 16.31 | 63.33 ± 19.08 |
| Change at Week 12 | -26.29 ± 20.77 | -13.99 ± 15.74 | -20.90 ± 18.20 |
PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Positive syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. Negative syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. General Psychopathology subscale ranges from 16 to112, higher change scores indicate worsening.
| Units on a scale | Paliperidone Extended Release (ER) |
|---|---|
| Positive: Baseline | 17.07 ± 6.53 |
| Positive: Change at Week 12 | -6.59 ± 6.30 |
| Negative: Baseline | 18.57 ± 6.66 |
| Negative: Change at Week 12 | -6.14 ± 5.99 |
| General psychopathology: Baseline | 34.44 ± 9.75 |
| General psychopathology: Change at Week 12 | -10.84 ± 10.21 |
The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28. Higher change score indicates greater severity.
| Units on a scale | Paliperidone Extended Release (ER) |
|---|---|
| Positive symptoms: Baseline | 21.61 ± 7.15 |
| Positive symptoms: Change at Week 12 | -8.16 ± 7.18 |
| Negative symptoms: Baseline | 19.15 ± 7.10 |
| Negative symptoms: Change at Week 12 | -6.53 ± 6.60 |
| Disorganized thoughts: Baseline | 14.13 ± 4.65 |
| Disorganized thoughts: Change at Week 12 | -4.13 ± 4.28 |
| Uncontrolled hostility/excitement: Baseline | 7.73 ± 3.83 |
| Uncontrolled hostility/excitement:Change at Week12 | -2.74 ± 3.63 |
| Anxiety/depression: Baseline | 7.45 ± 2.76 |
| Anxiety/depression: Change at Week 12 | -2.00 ± 2.67 |
PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Percentage of participants with at least 20 percent improvement of PANSS total score was measured.
| Percentage of participants | Lack of Efficacy Group | Lack of Tolerability Group | Other Group |
|---|---|---|---|
| Percentage of Participants With Response to Positive and Negative Syndrome Scale (PANSS) Total Score | 65.97 (59.95 to 71.99) | 51.72 (42.63 to 60.82) | 61.90 (47.22 to 76.59) |
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants". Higher change scores indicate worsening.
| units on a scale | Lack of Efficacy Group | Lack of Tolerability Group | Other Group |
|---|---|---|---|
| Baseline (n=237,115,41) | 4.54 ± 0.91 | 3.20 ± 1.11 | 3.86 ± 1.09 |
| Change at Week 12 (n=208,103,40) | -1.77 ± 0.09 | -1.01 ± 0.14 | -1.66 ± 0.23 |
PSP assesses the degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =\<30, functioning so poorly as to require intensive supervision.
| Units on a scale | Lack of Efficacy Group | Lack of Tolerability Group | Other Group |
|---|---|---|---|
| Baseline (n=238,115,41) | 53.16 ± 13.79 | 66.95 ± 12.89 | 66.00 ± 11.21 |
| Change at Week 12 (n=205,106,40) | 18.57 ± 16.87 | 10.09 ± 13.75 | 12.40 ± 13.33 |
Participants assessed their satisfaction with paliperidone ER on a 5-point scale: 1 (very good), 2 (good), 3 (moderate), 4 (poor) and 5 (very poor).
| Participants | Lack of Efficacy Group | Lack of Tolerability Group | Other Group |
|---|---|---|---|
| Baseline, Very satisfied (n=230,113,41) | 1 | 3 | 0 |
| Baseline, Satisfied (n=230,113,41) | 15 | 30 | 15 |
| Baseline, Generally satisfied (n=230,113,41) | 84 | 58 | 25 |
| Baseline, Dissatisfied (n=230,113,41) | 124 | 21 | 1 |
| Baseline, Very dissatisfied (n=230,113,41) | 6 | 1 | 0 |
| Week 12, Very satisfied (n=208,105,40) | 30 | 23 | 10 |
| Week 12, Satisfied (n=208,105,40) | 93 | 51 | 18 |
| Week 12, Generally satisfied (n=208,105,40) | 62 | 24 | 10 |
| Week 12, Dissatisfied (n=208,105,40) | 23 | 6 | 2 |
| Week 12, Very dissatisfied (n=208,105,40) | 0 | 1 | 0 |
The self-administered sleep VAS scale (0-100 milimeter \[mm\]) rates quality of sleep (QoS) and daytime drowsiness (DD). Participants indicate mark on the scale to represent how well they have slept in the previous 7 days, score ranges from 0 mm (very badly) to 100 mm (very well); and how often they have felt drowsy within the previous 7 days, from 0 mm (not at all) to 100 mm (all the time).
| mm | Lack of Efficacy Group | Lack of Tolerability Group | Other Group |
|---|---|---|---|
| Quality of sleep score: Baseline (n=233,115,41) | 60.76 ± 26.70 | 75.89 ± 20.24 | 70.31 ± 22.40 |
| Quality of sleep: Change at Week 12 (n=202,106,40) | 15.76 ± 29.46 | 2.90 ± 27.41 | 13.60 ± 26.94 |
| Daytime drowsiness score: Baseline (n=233,115,41) | 38.16 ± 23.70 | 44.77 ± 25.29 | 34.26 ± 23.64 |
| Daytime drowsiness:Change at Week 12(n=202,106,40) | -15.76 ± 27.52 | -21.66 ± 27.88 | -18.10 ± 26.87 |
Collected over Baseline up to Week 12. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone Extended Release (ER) | — | 1/403 (0.2%) | 227/403 (56.3%) |
| Event | Paliperidone Extended Release (ER) |
|---|---|
| DepressionPsychiatric disorders | 1/403 |
| Event | Paliperidone Extended Release (ER) |
|---|---|
| AkathisiaPsychiatric disorders | 74/403 |
| TremorNervous system disorders | 52/403 |
| DystoniaNervous system disorders | 35/403 |
| SomnolencePsychiatric disorders | 32/403 |
| InsomniaPsychiatric disorders | 26/403 |
| Extrapyramidal disorderNervous system disorders | 24/403 |
| Weight increasedInvestigations | 17/403 |
| DizzinessNervous system disorders | 17/403 |
| NauseaGastrointestinal disorders | 15/403 |
| Upper respiratory tract infectionInfections and infestations | 15/403 |
| Age Continuous(Years) | Paliperidone Extended Release (ER) |
|---|---|
| Mean | 30.88 ± 10.39 |
| Sex: Female, Male(Participants) | Paliperidone Extended Release (ER) |
|---|---|
| Female | 199 |
| Male | 195 |
No study locations are listed for this record.
The record gives a start of Jul 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Xian-Janssen Pharmaceutical Ltd. →